Form 10-Q Cullinan Oncology, Inc For: Sep 30 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024
Cullinan Oncology (NASDAQ:CGEM) versus Titan Pharmaceuticals (NASDAQ:TTNP) Financial Comparison themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) and Cullinan Oncology (NASDAQ:CGEM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Analyst Ratings This is a breakdown of […]
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer patients open to enrollment Initial monotherapy clinical data for CLN-619 presented at. -Today at 07:02 am- MarketScreener